116 related articles for article (PubMed ID: 31669883)
1. Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats.
Alves BEO; de Alencar AKN; Gamba LER; Trachez MM; da Silva JS; Araújo JSC; Montagnoli TL; Mendes LVP; Pimentel-Coelho PM; do M N Cunha V; Mendez-Otero R; Oliveira GMM; Lima LM; Barreiro EJ; Sudo RT; Zapata-Sudo G
Pharmacol Rep; 2019 Dec; 71(6):1190-1200. PubMed ID: 31669883
[TBL] [Abstract][Full Text] [Related]
2. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M
J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
Karabulut S; Coskun ZM; Bolkent S
Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.
Esposito G; Cappetta D; Russo R; Rivellino A; Ciuffreda LP; Roviezzo F; Piegari E; Berrino L; Rossi F; De Angelis A; Urbanek K
Br J Pharmacol; 2017 Nov; 174(22):4070-4086. PubMed ID: 27922176
[TBL] [Abstract][Full Text] [Related]
5. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemia-reperfusion injury in rats with diabetes mellitus type 2.
Bradic J; Milosavljevic I; Bolevich S; Litvitskiy PF; Jeremic N; Bolevich S; Zivkovic V; Srejovic I; Jeremic J; Jovicic N; Mitrovic S; Jakovljevic V
Clin Exp Pharmacol Physiol; 2021 Apr; 48(4):575-584. PubMed ID: 33352623
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin and shock wave-supported peripheral blood derived endothelial progenitor cell therapy effectively preserves residual renal function in chronic kidney disease in rat-role of dipeptidyl peptidase 4 inhibition.
Sung PH; Chen KH; Li YC; Chiang JY; Lee MS; Yip HK
Biomed Pharmacother; 2019 Mar; 111():1088-1102. PubMed ID: 30841422
[TBL] [Abstract][Full Text] [Related]
9. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
[TBL] [Abstract][Full Text] [Related]
10. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
[TBL] [Abstract][Full Text] [Related]
11. Potential impact of sitagliptin on collagen-derived dipeptides in diabetic osteoporosis.
Baerts L; Glorie L; Maho W; Eelen A; Verhulst A; D'Haese P; Covaci A; De Meester I
Pharmacol Res; 2015 Oct; 100():336-40. PubMed ID: 26342756
[TBL] [Abstract][Full Text] [Related]
12. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
Jackson EK; Mi Z; Tofovic SP; Gillespie DG
Hypertension; 2015 Jan; 65(1):238-49. PubMed ID: 25368027
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
Beraldo JI; Benetti A; Borges-Júnior FA; Arruda-Junior DF; Martins FL; Jensen L; Dariolli R; Shimizu MH; Seguro AC; Luchi WM; Girardi ACC
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010001
[TBL] [Abstract][Full Text] [Related]
14. Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD.
Benetti A; Martins FL; Sene LB; Shimizu MHM; Seguro AC; Luchi WM; Girardi ACC
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F285-F296. PubMed ID: 33346727
[TBL] [Abstract][Full Text] [Related]
15. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Sauvé M; Ban K; Momen MA; Zhou YQ; Henkelman RM; Husain M; Drucker DJ
Diabetes; 2010 Apr; 59(4):1063-73. PubMed ID: 20097729
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
17. New Benzofuran
Costa GC; Montagnoli TL; Da Silva JS; de Alencar AKN; Reina Gamba LE; Alves BEO; da Silva MMC; Trachez MM; do Nascimento JHM; Pimentel-Coelho PM; Mendez-Otero R; Lima LM; Barreiro EJ; Sudo RT; Zapata-Sudo G
Drug Des Devel Ther; 2020; 14():3337-3350. PubMed ID: 32884238
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.
Ramírez E; Picatoste B; González-Bris A; Oteo M; Cruz F; Caro-Vadillo A; Egido J; Tuñón J; Morcillo MA; Lorenzo Ó
Cardiovasc Diabetol; 2018 Jan; 17(1):12. PubMed ID: 29325553
[TBL] [Abstract][Full Text] [Related]
19. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats.
Zhou Y; Wang H; Man F; Guo Z; Xu J; Yan W; Li J; Pan Q; Wang W
Cardiovasc Drugs Ther; 2018 Dec; 32(6):541-552. PubMed ID: 30328028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
